Programme
9:00-9:25 Opening Remarks, Chemical Probes for Methyltransferases
Masoud Vedadi
Protein Arginine Methyltransferases (PRMTs)
9:30-10:00 Ernesto Guccione, Institute of Molecular and Cell Biology (IMCB), Singapore
"Dissecting the role of PRMT5: learning from development to target splicing in cancer therapy“
10:05-10:35 Mark Bedford, University of Texas, USA
"Arginine methylation – enzymes, readers & inhibitors“
10:40-11:10 Adam Frankel, University of British Columbia, Canada
“Peptides and small molecules get into the PRMT groove”
11:15-11:30 Coffee break
Medicinal Chemistry
11:30-11:55 Dafydd Owen, Pfizer, Cambridge , MA
“A First in Class Chemical Probe for SETD7”
12:00-12:25 Rima Al-Awar, Ontario Institute for Cancer Research, Toronto
“The Discovery and Optimization of Small Molecule Antagonists of the WDR5-MLL Interaction.”
12:30-12:55 Ramzi Sweis, AbbVie, Chicago, IL
“Discovery of A366, a Potent and Selective Inhibitor of Histone Methyltransferase G9a.”
1:00-2:00 Lunch
Protein Lysine Methyltransferases (PKMTs)
2:00-2:30 Yali Dou, University of Michigan, USA
"Characterizing and Targeting histone methyltransferase MLL1".
2:35-3:05 Jean-Francois Couture, University of Ottawa, Canada
"Structural studies of Ash2L; a multitasking trithorax protein “
3:10-3:40 Raymond Trievel, University of Michigan, USA
"Mechanistic Roles of Carbon-Oxygen Hydrogen Bonds in SET Domain Lysine Methyltransferases“
3:45-4:15 Albert Wong, University of Toronto, Canada
“Behavioural effects of histone methyltransferase inhibitors in the mouse”
4:20-4:45 Closing remarks
Cheryl Arrowsmith
Organizing Committee Masoud Vedadi Cheryl Arrowsmith Santha Santhakumar | Supported by the Department of Pharmacology and Toxicology University of Toronto |
| Sponsored by ChemNet, an NSERC CREATE medicinal chemistry training programme in partnership with the SGC and the pharmaceutical industry. |
